Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Duke Energy Corp (DUK) Price & Performance

Biogen IncTrade
Duke Energy CorpTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Duke Energy Corp — how do they compare? Biogen Inc trades at $206.51 (market cap $30.13B), while Duke Energy Corp trades at $123.38 (market cap $96.05B). The key difference: Duke Energy Corp is far larger — about 3.2× Biogen Inc's market cap, and Duke Energy Corp pays a 3.52% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.

BIIBDUK
Market Cap
$30.13B$96.05B
Sector
HealthUtilities
52-Week High
$216.63$133.46
52-Week Low
$128.93$113.99
Enterprise Value
$37.20B$188.56B
Dividend Yield
3.52%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

Duke Energy Corp

Duke Energy (DUK) trades at $122.97, up 1.46% today, with a bearish technical signal but strong fundamentals. Recent earnings beat estimates for three consecutive quarters, with Q2 2026 EPS at $1.43 versus $1.30 expected. The company maintains solid profitability, with a net income margin of 15.78% and ROE of 10.01%. Cash flow trends show consistent operational strength, though investing outflows remain high due to infrastructure spending.

The outlook is mixed: analyst consensus is a Buy with a $136.17 price target, but technical indicators signal near-term caution. Key risks include regulatory scrutiny and high debt levels, while opportunities lie in data-center demand growth and dividend stability. Investors should weigh strong fundamentals against bearish technicals and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Duke Energy Corp

Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure

Read more on DUK